pre-ipo
Stage
1
Investors
About
Selecta Biosciences develops tolerogenic Synthetic Vaccine Particles (SVP™) to reduce unwanted immune responses, enabling non-immunogenic biologic therapies for rare and serious diseases such as gout.
Explore Selecta Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.